Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • a_mt
    Member
    • Jul 2012
    • 34

    some basic questions about duplicate removal ?

    Hi all,

    I am using the GATK pipeline for pre processing bam files after alignment with bwa mem. The original bam files after alignment shows I have (samtools flagstat command) - 173,460,757 reads (this is deep sequening exome data captured with agilent sure select 50 mb).

    But after removing duplicates with Picard, I am left with 14,651,238 reads !! Thats like mere 20X coverage.

    1. I would like to know whether this is normal in exome seq to find such huge amount duplicates? And some of the threads on other forums say its not wise to remove duplicates from deep sequencing data. Can anyone provide me some suggestions on this, like how you guys proceed in such scenario ?

    2. And what is the difference between marking duplicates and removing duplicates ? I know marking adds a tag instead of completely removing the read. But, if the duplicate marked reads are not used in any of the downstream steps (like SNP calling) why is it suggested to simply marking it instead of removing it?

    3. And while calculating coverage do we have to consider duplicate reads as well (original bam) or the final bam file with dups removed ?

    Thank you.
  • Brian Bushnell
    Super Moderator
    • Jan 2014
    • 2709

    #2
    If you had low library complexity due to insufficient DNA, overamplification, contamination, or highly-biased capture, a lot of duplicates will be present. Sounds like there were problems with your library prep and maybe it should be redone; that level is much higher than I'd expect. But, just run pileup and see if there is enough coverage for whatever you're doing, which depends on the fraction of the area covered to at least X depth rather than the average coverage.

    PCR duplicates should be removed before calling variations. But I would suggest removing only exact duplicate reads, rather than anything mapping to the same location even if they have some different base calls. And just to clarify, are these paired reads that you're removing based on both reads mapping to the same location?

    Removing duplicates rather than marking them is more efficient as downstream programs don't need to process as much data. But, you can use marked duplicates to generate consensus if you want, when reads are low quality.

    I use the unique coverage when calling variations as it's more relevant.

    Comment

    Latest Articles

    Collapse

    • SEQadmin2
      Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
      by SEQadmin2


      Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

      The systematic characterization of the human proteome has
      ...
      07-20-2026, 11:48 AM
    • SEQadmin2
      Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
      by SEQadmin2



      Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
      ...
      07-09-2026, 11:10 AM
    • SEQadmin2
      Cancer Drug Resistance: The Lingering Barrier to Rising Survival
      by SEQadmin2



      Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

      There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
      07-08-2026, 05:17 AM

    ad_right_rmr

    Collapse

    News

    Collapse

    Topics Statistics Last Post
    Started by SEQadmin2, 07-24-2026, 12:17 PM
    0 responses
    31 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-23-2026, 11:41 AM
    0 responses
    23 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-20-2026, 11:10 AM
    0 responses
    215 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-13-2026, 10:26 AM
    0 responses
    79 views
    0 reactions
    Last Post SEQadmin2  
    Working...